Pomalong 1mg (Pomalidomide)

Contact us for more information
Wishlist Compare
Cipla Ltd

Pomalong 1mg (Pomalidomide)

ManufacturerCipla LtdBrand namePomalongInternational trade namepomalystActive substancePomalidomideStrength1mgCategoryAnti Cancer

Description  of  Pomalong 1mg (Pomalidomide 1mg)

Pomalong 1mg (Pomalidomide 1mg)is a Natco pharma product which is endorsed by FDA, containing an active anti-cancer drug called Pomalidomide. Pomalong 1mg (Pomalidomide 1mg) is available as orally bioavailable thalidomide derivative with various therapeutic activities such as; Immuno modulatory Anti-angiogenesis Anti-neoplastic Pomalong 1mg (Pomalidomide 1mg)  is similar to thalidomide & Lenalidomide with related to decreased rate of serum aminotransferase elevations during treatment. This may leads to severe liver injury. Pomalong 1mg (Pomalidomide 1mg)is involved in the treatment for regression & unmanageable multiple myeloma. Pomalong 1mg (Pomalidomide 1mg)  is used in the patients who are failing to response for Lenalidomide treatment. Pomalong 1mg (Pomalidomide 1mg) is used in combination with dexamethasone.

INDICATIONS of  Pomalong 1mg (Pomalidomide 1mg)

The major therapeutic indication of Pomalong 1mg (Pomalidomide 1mg) is involved in the treatment of multiple myeloma.
This treatment is occurred by combining with dexamethasone for reducing the side effect associated with Pomalong 1mg (Pomalidomide 1mg)
Pomalong 1mg (Pomalidomide 1mg) is majorly indicated in patients who are not reacts for prior two therapies like Lenalidomide & proteasome inhibitor.

MECHANISM OF ACTION  of  Pomalong 1mg (Pomalidomide 1mg)

Pomalidomide directly inhibits angiogenesis and myeloma cell growth. This dual effect is central to its activity in myeloma, rather than other pathways such as TNF alpha inhibition, since potent TNF inhibitors including rolipram and pentoxifylline do not inhibit myeloma cell growth or angiogenesis. Upregulation of interferon gamma, IL-2 and IL-10 as well as downregulation of IL-6 have been reported for pomalidomide. These changes may contribute to pomalidomide's anti-angiogenic and anti-myeloma activities.

 SIDE EFFECTS  of  Pomalong 1mg (Pomalidomide 1mg)

Commonly reported side effects of pomalidomide include: anemia, anxiety, confusion, dizziness, neuropathy, neutropenia, peripheral neuropathy, and thrombocytopenia. 

Other side effects include: acute myocardial infarction, cerebrovascular accident, and febrile neutropenia. See below for a comprehensive list of adverse effects.

PRECAUTIONS  of  Pomalong 1mg (Pomalidomide 1mg)


There are two major worsening condition may occur during the treatment using with Pomalong 1mg (Pomalidomide 1mg).

Embryo fetal damage

Pomalong 1mg (Pomalidomide 1mg)capsules are contraindicated to pregnancy period. During the treatment, patients avoid to becoming pregnant. Use effective contraceptives for preventing pregnancy during therapy.

Venous & arterial thromboembolism

Patient who are receiving Pomalong 1mg (Pomalidomide 1mg)capsules have chance of getting deep vein thrombosis, pulmonary embolism, myocardial infarction & stroke. This type of condition should be treated by initiating prophylactic anti-thrombotic drugs. The patients who are acquiring this condition then thromboprophylaxis should be provided


DRUG INTERACTION of  Pomalong 1mg (Pomalidomide 1mg)

Pomalong 1mg (Pomalidomide 1mg) metabolism is mediated by CYP1A2 & CYP3A4. The concomitant use of Pomalong 1mg (Pomalidomide 1mg)with CYP1A2 drugs like Fluoxamine causes elevation of Cmax & AUC of Pomalong 1mg (Pomalidomide 1mg)and concludes as increased concentration of Pomalong 1mg (Pomalidomide 1mg) leads to higher extent of adverse effects associated with Pomalong 1mg (Pomalidomide 1mg) In this condition, reduce the dose of Pomalong 1mg (Pomalidomide 1mg) and recommended.

DOSAGE of  Pomalong 1mg (Pomalidomide 1mg)

The prescribed dose of Pomalong in multiple myeloma is 4mg should be administered orally as once a day on day 1 to 21 of reciprocated 28-day cycles.
Pomalong 1mg (Pomalidomide 1mg) should be concomitant with dexamethasone.
Pomalong 1mg (Pomalidomide 1mg) Capsules should be taken with or without food.
During hematological toxicities:
ANC (absolute neutrophils count) <500/mcl: Postpone the Pomalong therapy and provide CBC weekly
ANC more than or equal to 500/mcl: Continue the Pomalong 3mg daily.
Platelets count <25,000/mcL: postpone the Pomalong treatment & follow the CBC
>50,000/mcL: continue 3mg of Pomalong
Pomalong 1mg (Pomalidomide 1mg) with potent CYP1A2 inhibitor:
During this combination reduce the dose of Pomalong by 50%
In renal impairment:
Initial dose of Pomalong is 3mg
In hepatic impairment:
Mild to moderate condition, an initial dose of Pomalong is 3mg; in severe condition, the initial dose of Pomalong is 2mg.

STORAGE  of  Pomalong 1mg (Pomalidomide 1mg)

Pomalong 1mg (Pomalidomide 1mg) should be stored at room temperature of 20℃ to 25℃ Protect from light Kept in dry & cool place.

MISSED DOSE of  Pomalong 1mg (Pomalidomide 1mg)

Have the missed dose immediately before next dose duration
Next dose time arrived then left off the missed dose and follows regular schedule.
Avoid taking extra dose at same time.
Please consult the doctor for further details.

Brand name:
International trade name:
Active substance:
Anti Cancer
Cipla Ltd
21 Capsules
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India